Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. China
  4. Shanghai Stock Exchange
  5. Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
  6. Financials
    600196   CNE000000X38

SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.

(600196)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Valuation
Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization1 57 94865 086125 791138 049--
Entreprise Value (EV)1 72 60477 050139 217155 947154 215158 721
P/E ratio 21,7x20,5x37,8x31,7x24,8x20,8x
Yield 1,38%1,47%0,80%0,87%1,22%1,51%
Capitalization / Revenue 2,34x2,28x4,15x3,77x3,26x2,87x
EV / Revenue 2,94x2,70x4,59x4,26x3,64x3,30x
EV / EBITDA 21,1x13,1x22,2x29,8x21,7x16,4x
Price to Book 2,13x2,14x3,74x3,76x3,41x3,06x
Nbr of stocks (in thousands) 2 563 0612 562 8992 562 8992 562 899--
Reference price (CNY) 23,326,654,058,758,758,7
Announcement Date 03/25/201903/30/202003/29/2021---
1 CNY in Million
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales1 24 71428 58530 30737 55043 54047 667
EBITDA1 3 4375 8746 2825 8118 3178 223
Operating profit (EBIT)1 2 0914 4944 7213 2454 8007 022
Operating Margin 8,46%15,7%15,6%8,64%11,0%14,7%
Pre-Tax Profit (EBT)1 3 5804 5264 6786 2578 0429 694
Net income1 2 7083 3223 6635 0086 0077 417
Net margin 11,0%11,6%12,1%13,3%13,8%15,6%
EPS2 1,071,301,431,852,372,83
Dividend per Share2 0,320,390,430,510,720,89
Announcement Date 03/25/201903/30/202003/29/2021---
1 CNY in Million
2 CNY
Income Statement Evolution (Quarterly data)
Fiscal Period: December 2020 Q3 2021 Q1 2021 Q2 2021 Q3 2021 Q4 2022 Q1
Net sales1 8 0758 0568 8968 83711 6168 082
EBITDA ------
Operating profit (EBIT)1 -1 1592 1687091 597725
Operating Margin -14,4%24,4%8,03%13,7%8,97%
Pre-Tax Profit (EBT) ------
Net income ------
Net margin ------
EPS2 0,300,330,640,470,520,49
Dividend per Share ------
Announcement Date 10/29/202004/26/202108/23/2021---
1 CNY in Million
2 CNY
Previous periodNext period
Balance Sheet Analysis
Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt1 14 65711 96413 42617 89816 16620 673
Net Cash position1 ------
Leverage (Debt / EBITDA) 4,26x2,04x2,14x3,42x2,27x2,14x
Free Cash Flow1 -367-706-1 8571 2853 1824 595
ROE (Net Profit / Equities) 10,2%11,6%10,8%11,8%13,5%15,2%
Shareholders' equity1 26 59528 75933 79039 65146 43346 392
ROA (Net Profit / Asset) 4,09%4,53%4,58%4,21%5,65%6,57%
Assets1 66 25773 34179 904111 079110 733107 468
Book Value Per Share2 10,912,414,415,617,219,2
Cash Flow per Share2 1,151,261,011,622,002,78
Capex1 3 3173 9284 4372 9022 8072 938
Capex / Sales 13,4%13,7%14,6%7,94%6,63%6,10%
Announcement Date 03/25/201903/30/202003/29/2021---
1 CNY in Million
2 CNY
Key data
Capitalization (CNY) 138 048 920 623
Capitalization (USD) 21 349 972 258
Net sales (CNY) 30 306 981 260
Net sales (USD) 4 687 489 871
Number of employees 34 375
Sales / Employee (CNY) 881 658
Sales / Employee (USD) 136 363
Free-Float 57,5%
Free-Float capitalization (CNY) 79 392 398 333
Free-Float capitalization (USD) 12 278 440 819
Avg. Exchange 20 sessions (CNY) 1 896 138 494
Avg. Exchange 20 sessions (USD) 293 270 052
Average Daily Capital Traded 1,37%
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA